2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

metabolic conversion

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dyes

2

Biochemical Assay Reagents

6

Natural
Products

14

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0390S1
    L-Glutamine-13C5
    Maximum Cited Publications
    9 Publications Verification

    L-Glutamic acid 5-amide-13C5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 13C5 is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-13C5
  • HY-B0504S
    Creatinine-d3
    5 Publications Verification

    NSC13123-d3

    		 Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor Metabolic Disease Cancer
    Creatinine-d3 is a deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine-d3
  • HY-N0390S
    L-Glutamine-15N
    3 Publications Verification

    L-Glutamic acid 5-amide-15N

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N
  • HY-N0390S8
    L-Glutamine-15N2
    1 Publications Verification

    L-Glutamic acid 5-amide-15N2

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N2 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N2
  • HY-D1736
    BODIPY FL-C16

    		Fluorescent Dye Others
    BODIPY FL-C16 is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with Kd values of 270 nM and 330 nM, respectively. BODIPY FL-C16 is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles .
    BODIPY FL-C16
  • HY-B0504
    Creatinine
    5+ Cited Publications

    NSC13123

    		 Endogenous Metabolite GABA Receptor iGluR Infection Neurological Disease Metabolic Disease Cancer
    Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine
  • HY-N0390S9
    L-Glutamine-15N-1
    3 Publications Verification

    L-Glutamic acid 5-amide-15N-1

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N-1
  • HY-B0504S2
    Creatinine-d5

    NSC13123-d5

    		 Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor Metabolic Disease
    Creatinine-d5 is the deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine-d5
  • HY-N0390S2
    L-Glutamine-d5
    1 Publications Verification

    L-Glutamic acid 5-amide-d5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine-d5 is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-d5
  • HY-N0390S6
    L-Glutamine-13C5,15N2

    L-Glutamic acid 5-amide-13C5,15N2

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 13C5, 15N2 is the 13C- and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-13C5,15N2
  • HY-134356
    AICA-riboside, 5′-phosphate

    AICAR-5'-MP

    		 Endogenous Metabolite Others
    AICA-riboside, 5′-phosphate is AICA riboside with a phosphate group. The functions of AICA riboside include: 1) conversion into AMP mimetic to selectively activate AMPK; 2) competition with adenosine for the uptake of nucleoside transporters, reversible blocking of adenosine reuptake, increasing extracellular adenosine concentration, and indirectly activating adenosine A1 receptors. AICA riboside is involved in metabolic regulation (promoting catabolism and inhibiting anabolism) and adenosine-dependent neuroprotection (inhibiting excitatory synaptic transmission). AICA riboside can be used in the study of metabolic diseases (such as diabetes and obesity) and neurological diseases (such as ischemia and epilepsy), and has central nervous system protective activity .
    AICA-riboside, 5′-phosphate
  • HY-E70558
    5α-reductase, Rat(Sprague-Dawley) Liver

    		5 alpha Reductase Metabolic Disease
    5α-reductase, Rat (Sprague-Dawley) Liver is an enzyme involved in steroid metabolism and participates in the androgen metabolic pathway. 5α-reductase, Rat (Sprague-Dawley) Liver catalyzes the conversion of testosterone to 5α-dihydrotestosterone (DHT). DHT plays important roles in the development of male sex organs, hair growth, prostate function, and other aspects .
    5α-reductase, Rat(Sprague-Dawley) Liver
  • HY-177705
    ACSL5-IN-2

    		ACSL Family Drug Derivative Metabolic Disease Cancer
    ACSL5-IN-2 (Compound B) is an Acyl CoA synthetase 5 (ACSL5) inhibitor. ACSL5-IN-2 can block the conversion of long-chain fatty acids (such as palmitic acid and oleic acid) into acyl-CoA, and intervene in the fatty acid metabolism pathway. ACSL5-IN-2 can inhibit cancer cells growth. ACSL5-IN-2 can be used for the research of cancer and metabolic disease, such as colon cancer and dysfunction-associated Steatohepatitis .
    ACSL5-IN-2
  • HY-N0390R
    L-Glutamine (Standard)
    25+ Cited Publications

    L-Glutamic acid 5-amide (Standard)

    		 Reference Standards mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine (Standard)
  • HY-B0504R
    Creatinine (Standard)

    NSC13123 (Standard)

    		 Reference Standards Endogenous Metabolite iGluR GABA Receptor Metabolic Disease Cancer
    Creatinine (Standard) is the analytical standard of Creatinine. This product is intended for research and analytical applications. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine (Standard)
  • HY-113629
    2-Keto-D-Glucose

    D-Glucosone; D-Arabino-hexos-2-ulose

    		 Drug Metabolite Infection
    2-Keto-D-Glucose (D-Glucosone) is a key intermediate in a secondary metabolic pathway leading to the antibiotic Cortalcerone. 2-Keto-D-Glucose is also an intermediate in the conversion of D-glucose into D-fructose. 2-Keto-D-Glucose is found in various natural sources, including fungi, algae, and shellfish .
    2-Keto-D-Glucose
  • HY-B0504S1
    Creatinine-13C

    NSC13123-13C

    		 Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor Metabolic Disease
    Creatinine- 13C is the 13C-labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine-13C
  • HY-B1713A
    DL-Ornithine hydrochloride

    DL-(±)-Ornithine hydrochloride

    		 Endogenous Metabolite Metabolic Disease
    DL-Ornithine (DL-(±)-Ornithine) hydrochloride is an amino acid and also a urea cycle promoter. DL-Ornithine hydrochloride has the characteristics of low metabolic rate and rapid excretion, and only the L-enantiomer undergoes decarboxylation. In mice inoculated with L-1210 leukemia cells, DL-Ornithine hydrochloride is excreted in urine in its original form, and its conversion to carbon dioxide within 24 h is negligible. DL-Ornithine hydrochloride is mainly used in the urea cycle to eliminate excess nitrogen in the body and protect the kidneys .
    DL-Ornithine hydrochloride
  • HY-N0390S5
    L-Glutamine-1-13C
    1 Publications Verification

    L-Glutamic acid 5-amide-1-13C

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine-1- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-1-13C
  • HY-N0390S4
    L-Glutamine-5-13C

    L-Glutamic acid 5-amide-5-13C

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine-5- 13C is the 13C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-5-13C
  • HY-173447
    8-BuS-AMP

    		NTPDase CD73 Cancer
    8-BuS-AMP is a NTPDase1 inhibitor and a CD73/CD39 inhibitor, with an IC50 of 35 μM and a Ki value of 0.292 μM against human NTPDase1; its Ki values against human CD73 and CD39 are 1.19 μM and 0.847 μM, respectively. 8-BuS-AMP binds to the substrate-binding pockets of NTPDase1 and CD73 to effectively block the conversion of ATP and AMP to adenosine, thereby enhancing the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP possesses excellent enzymatic hydrolysis resistance and metabolic stability, resists hydrolysis by multiple NTPDase subtypes, and shows no activity against P2Y1 and P2Y12 receptors. 8-BuS-AMP can be used in purinergic signaling pathway and cancer-related studies .
    8-BuS-AMP
  • HY-N0390S3
    L-Glutamine-13C5,15N2,d5

    L-Glutamic acid 5-amide-13C5,15N2,d5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 13C5, 15N2,d5 is the deuterium, 13C-, and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-13C5,15N2,d5
  • HY-W552257
    Hydroxypyruvic acid phosphate

    		Drug Intermediate Others
    Hydroxypyruvic acid phosphate serves as a crucial metabolic intermediate in the biosynthesis of L-Serine (HY-N0650), being formed from the conversion of the glycolytic intermediate 3-phosphoglycerate through the action of 3-phosphoglycerate dehydrogenase.
    Hydroxypyruvic acid phosphate
  • HY-B0504S5
    Creatinine-15N

    NSC13123-15N

    		 Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor Metabolic Disease Cancer
    Creatinine- 15N (NSC13123- 15N) is the 15N-labeled Creatinine (HY-B0504). Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine-15N
  • HY-P2815
    Creatinine deiminase

    		Biochemical Assay Reagents Others
    Creatinine deiminase is a hydrolytic enzyme. Creatinine deiminase plays a crucial role in the conversion of the metabolic waste creatinine into creatine. Creatinine deiminase is a creatine bioanalytical tool. Creatinine deiminase can be used to construct a novel creatinine-sensitive biosensor when adsorbed on a silicate-modified pH-sensitive field-effect transistor (pH-FET) .
    Creatinine deiminase
  • HY-121390
    Lasiocarpine

    		Endogenous Metabolite Cancer
    Lasiocarpine, a hepatotoxic pyrrolizidine alkaloid (PA), causes fatal liver veno-occlusive disease in vivo. Lasiocarpine is toxic only after its metabolic conversion to the toxic intermediate, including dehydrolasiocarpine and N-oxide .
    Lasiocarpine
  • HY-P2991
    Galactose 1-phosphate uridylyltransferase

    		Endogenous Metabolite Others
    Galactose-1-phosphate uridyl transferase (GALT) catalyzes the second step of the Leloir pathway of galactose metabolism, namely the conversion of galactose to glucose. Galactose-1-phosphate uridylyltransferase absence results in classic galactosemia in humans and can be used for metabolic disease research .
    Galactose 1-phosphate uridylyltransferase
  • HY-179539
    ISR activator 3

    		Eukaryotic Initiation Factor (eIF) Neurological Disease Inflammation/Immunology
    ISR activator 3 (Compound cc81) is the active metabolite of A8. ISR activator 3 activates the integrated stress response (ISR) by binding to RIG-I (KD ≈ 0.55 μM), without inducing lipid droplet clearance. ISR activator 3 enhances the interferon response under viral mimicry signals. ISR activator 3 can be used for research on neurodegenerative diseases and immune stress .
    ISR activator 3
  • HY-121029
    Bisegliptin

    KRP-104

    		 Histone Methyltransferase Metabolic Disease
    Bisegliptin (KRP-104) is a small molecule compound with antidiabetic activity. Bisegliptin is metabolized mainly by converting the cyano group to the carboxylic acid form, and DPP-4 plays a partial role in its metabolism. The carboxylic acid metabolite of bisegliptin can be detected both in vivo and in vitro. In rat experiments, the plasma concentration of the carboxylic acid metabolite of bisegliptin was affected by other DPP inhibitors, showing the complexity of its metabolic process. The amide intermediate of bisegliptin was detected both in vivo and in vitro, and its conversion rate was significantly faster than that of the parent compound when incubated with DPP-4 .
    Bisegliptin
  • HY-14156
    11β-HSD1-IN-15

    		11β-HSD Metabolic Disease
    11β-HSD1-IN-15 is an inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1). 11β-HSD1-IN-15 blocks the conversion of corticosterone to cortisol by binding to the active site of the 11β-HSD1 enzyme. 11β-HSD1-IN-15 can be used to investigate the role of 11β-HSD1 enzymes IN the development of metabolic syndrome, obesity, cognitive decline and type 2 diabetes .
    11β-HSD1-IN-15
  • HY-N0390S7
    L-Glutamine-15N2,d5

    L-Glutamic acid 5-amide-15N2,d5

    		 Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine- 15N2,d5 is the deuterium and 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine-15N2,d5
  • HY-123273
    (Rac)-Metyrapol

    		11β-HSD Metabolic Disease
    Metyrapol is a steroid 11β-hydroxylase inhibitor. Metyrapol blocks the conversion of deoxycorticosterone to corticosterone in rat adrenal homogenates. Metyrapol can be used in the study of metabolic diseases .
    (Rac)-Metyrapol
  • HY-121390A
    Lasiocarpine hydrochloride

    		Endogenous Metabolite Cancer
    Lasiocarpine hydrochloride, a hepatotoxic pyrrolizidine alkaloid (PA), causes fatal liver veno-occlusive disease in vivo. Lasiocarpine hydrochloride is toxic only after its metabolic conversion to the toxic intermediate, including dehydrolasiocarpine and N-oxide .
    Lasiocarpine hydrochloride
  • HY-W552257A
    Hydroxypyruvic acid phosphate lithium

    		Drug Intermediate Others
    Hydroxypyruvic acid phosphate lithium serves as a crucial metabolic intermediate in the biosynthesis of L-Serine (HY-N0650), being formed from the conversion of the glycolytic intermediate 3-phosphoglycerate through the action of 3-phosphoglycerate dehydrogenase.
    Hydroxypyruvic acid phosphate lithium
  • HY-E70959
    β-Hydroxybutyrate Dehydrogenase, Pseudomonas lemoignei

    		Endogenous Metabolite Metabolic Disease
    β-Hydroxybutyrate Dehydrogenase, Pseudomonas lemoignei (EC 1.1.1.30) is a soluble cytosolic enzyme that does not require a phospholipid allosteric activator. β-Hydroxybutyrate Dehydrogenase, Pseudomonas lemoignei is required for the utilization of ketone bodies as a source of metabolic energy. β-Hydroxybutyrate Dehydrogenase, Pseudomonas lemoignei catalyzes the oxidation of 3-hydroxybutyrate to acetoacetate, the first step in the conversion of ketone bodies to citric acid, which is then further metabolized via the tricarboxylic acid cycle (Krebs cycle).
    β-Hydroxybutyrate Dehydrogenase, Pseudomonas lemoignei
  • HY-E70947
    β-Hydroxybutyrate Dehydrogenase, Rhodopseudomonas sphaeroides

    		Endogenous Metabolite Metabolic Disease
    β-Hydroxybutyrate Dehydrogenase, Rhodopseudomonas sphaeroides (EC 1.1.1.30) is a soluble cytosolic enzyme that does not require a phospholipid allosteric activator. β-Hydroxybutyrate Dehydrogenase, Rhodopseudomonas sphaeroides is required for the utilization of ketone bodies as a source of metabolic energy. β-Hydroxybutyrate Dehydrogenase, Rhodopseudomonas sphaeroides catalyzes the oxidation of 3-hydroxybutyrate to acetoacetate, the first step in the conversion of ketone bodies to citric acid, which is then further metabolized via the tricarboxylic acid cycle (Krebs cycle).
    β-Hydroxybutyrate Dehydrogenase, Rhodopseudomonas sphaeroides
  • HY-178691
    11β-HSD1-IN-24

    		11β-HSD Metabolic Disease
    11β-HSD1-IN-24 (Compound 10l) is a potent and selective 11β-HSD1 inhibitor with an IC50 of 0.5 nM. 11β-HSD1-IN-24 can effectively block the conversion of inactive Cortisone (HY-17461) to active Cortisol (HY-N0583). 11β-HSD1-IN-24 can be used for the research of metabolic disease, such as type 2 diabetes .
    11β-HSD1-IN-24
  • HY-DY1102
    BODIPY FL-C16 (solution)

    		Fluorescent Dye Others
    BODIPY FL-C16 (solution) is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 (solution) also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with Kd values of 270 nM and 330 nM, respectively. BODIPY FL-C16 (solution) is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles .
    Solvent and concentration: DMSO: 5 mM
    BODIPY FL-C16 (solution)
  • HY-N0390G
    L-Glutamine

    		mTOR NF-κB STAT HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na +-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .
    L-Glutamine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: